Alejandro Llanos-Chea1,2, Jason M Shapiro3,4, Rachel W Winter5,6, Logan Jerger1,2, Timothy Menz3,4, Meghan Gibson3,4, Alison M Friedmann1,2, Diana Treaba7,8, Konstantinos Papamichael9,10, Adam S Cheifetz9,10, Sonia Friedman5,6, Matthew J Hamilton5,6, Harland S Winter11,12. 1. Pediatric Gastroenterology and Nutrition, Massachusetts General Hospital, CRPZ 5-560, 175 Cambridge Street, Boston, MA, 02114, USA. 2. Harvard Medical School, CRPZ 5-560, 175 Cambridge Street, Boston, MA, 02114, USA. 3. Division of Pediatric Gastroenterology, Nutrition, and Liver Diseases, Hasbro Children's Hospital and Rhode Island Hospital, Hasbro Lower Level, 593 Eddy St., Providence, RI, 02903, USA. 4. Warren Alpert Medical School of Brown University, Hasbro Lower Level, 593 Eddy St., Providence, RI, 02903, USA. 5. Division of Gastroenterology, Brigham and Women's Hospital, Crohn's and Colitis Center, 75 Francis Street, Boston, MA, 02115, USA. 6. Harvard Medical School, 75 Francis Street, Boston, MA, 02115, USA. 7. Department of Pathology, Rhode Island Hospital, The Miriam Hospital, Brown University, Box G-E5, Providence, RI, 02912, USA. 8. Warren Alpert Medical School of Brown University, Brown University, Box G-E5, Providence, RI, 02912, USA. 9. Division of Gastroenterology, Beth Israel Deaconess Medical Center, Beth Israel Deaconess Med Ctr., 330 Brookline Avenue, Rabb Rose 1, Boston, MA, 02215, USA. 10. Harvard Medical School, Beth Israel Deaconess Med Ctr., 330 Brookline Avenue, Rabb Rose 1, Boston, MA, 02215, USA. 11. Pediatric Gastroenterology and Nutrition, Massachusetts General Hospital, CRPZ 5-560, 175 Cambridge Street, Boston, MA, 02114, USA. hwinter@mgh.harvard.edu. 12. Harvard Medical School, CRPZ 5-560, 175 Cambridge Street, Boston, MA, 02114, USA. hwinter@mgh.harvard.edu.
Abstract
BACKGROUND: Inflammatory bowel diseases (IBD) are often treated with anti-tumor necrosis factor alpha (anti-TNFα) medications. Concomitant treatment of IBD with anti-TNFα agents and immunomodulators appears to be associated with an increased risk for lymphoma. METHODS: Patients who developed lymphoma while on monotherapy with an anti-TNFα agent were identified at three centers. Institutional Review Board approval was obtained. RESULTS: Five adolescents and young adult patients with pediatric-onset IBD who were treated with infliximab (IFX) without exposure to thiopurines were subsequently diagnosed with lymphoma. Three of the five patients had bone involvement at presentation. Epstein-Barr virus was positive in 2 cases. Median time from diagnosis of IBD and exposure to IFX prior to diagnosis of lymphoma was 5 and 4.3 years, respectively. CONCLUSIONS: This case series reports long-term follow-up for young patients with IBD who were treated with IFX monotherapy and developed lymphoma. Three of the five patients had bone involvement. In general, the risk of lymphoma following exposure to anti-TNFα medications alone remains low, but the incidence of primary bone lymphomas in IBD has not been reported. Studies examining longer exposure times may be needed to determine the true lymphoma risk in patients treated with IFX monotherapy.
BACKGROUND: Inflammatory bowel diseases (IBD) are often treated with anti-tumor necrosis factor alpha (anti-TNFα) medications. Concomitant treatment of IBD with anti-TNFα agents and immunomodulators appears to be associated with an increased risk for lymphoma. METHODS: Patients who developed lymphoma while on monotherapy with an anti-TNFα agent were identified at three centers. Institutional Review Board approval was obtained. RESULTS: Five adolescents and young adult patients with pediatric-onset IBD who were treated with infliximab (IFX) without exposure to thiopurines were subsequently diagnosed with lymphoma. Three of the five patients had bone involvement at presentation. Epstein-Barr virus was positive in 2 cases. Median time from diagnosis of IBD and exposure to IFX prior to diagnosis of lymphoma was 5 and 4.3 years, respectively. CONCLUSIONS: This case series reports long-term follow-up for young patients with IBD who were treated with IFX monotherapy and developed lymphoma. Three of the five patients had bone involvement. In general, the risk of lymphoma following exposure to anti-TNFα medications alone remains low, but the incidence of primary bone lymphomas in IBD has not been reported. Studies examining longer exposure times may be needed to determine the true lymphoma risk in patients treated with IFX monotherapy.
Authors: Jeffrey S Hyams; Marla C Dubinsky; Robert N Baldassano; Richard B Colletti; Salvatore Cucchiara; Johanna Escher; William Faubion; John Fell; Benjamin D Gold; Anne Griffiths; Sibylle Koletzko; Subra Kugathasan; James Markowitz; Frank M Ruemmele; Gigi Veereman; Harland Winter; Nicholas Masel; Chu Ri Shin; Kezhen L Tang; Meena Thayu Journal: Gastroenterology Date: 2017-02-11 Impact factor: 22.682
Authors: Carlo Messina; David Christie; Emanuele Zucca; Mary Gospodarowicz; Andrés J M Ferreri Journal: Cancer Treat Rev Date: 2015-02-07 Impact factor: 12.111
Authors: Parambir S Dulai; Kimberly D Thompson; Heather B Blunt; Marla C Dubinsky; Corey A Siegel Journal: Clin Gastroenterol Hepatol Date: 2014-01-22 Impact factor: 11.382
Authors: Corey A Siegel; Sadie M Marden; Sarah M Persing; Robin J Larson; Bruce E Sands Journal: Clin Gastroenterol Hepatol Date: 2009-01-24 Impact factor: 11.382